Education
About Us
Working with TipRanks
Follow Us
Zelira Therapeutics Ltd. (ZLDAF)
:ZLDAF
Total Valuation
Zelira Therapeutics has a market cap or net worth of $3.48M. The enterprise value is $27.86M.
Market Cap$3.48M
Enterprise Value$27.86M
Share Statistics
Zelira Therapeutics has 11,897,155 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,897,155
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Zelira Therapeutics’s return on equity (ROE) is 8.10 and return on invested capital (ROIC) is -326.20%.
Return on Equity (ROE)8.10
Return on Assets (ROA)-7.05
Return on Invested Capital (ROIC)-326.20%
Return on Capital Employed (ROCE)3.11
Revenue Per Employee11.87K
Profits Per Employee-4.57M
Employee Count8
Asset Turnover0.02
Inventory Turnover0.07
Valuation Ratios
The current PE Ratio of Zelira Therapeutics is -0.10. Zelira Therapeutics’s PEG ratio is 0.52.
PE Ratio-0.10
PS Ratio0.00
PB Ratio1.29
Price to Fair Value-0.81
Price to FCF-5.65
Price to Operating Cash Flow-5.65
PEG Ratio0.52
Income Statement
In the last 12 months, Zelira Therapeutics had revenue of 94.95K and earned -36.57M in profits. Earnings per share was -3.22.
Revenue94.95K
Gross Profit10.28K
Operating Income-5.94M
Pretax Income-37.66M
Net Income-36.57M
EBITDA-36.44M
Earnings Per Share (EPS)-3.22
Cash Flow
In the last 12 months, operating cash flow was -5.29M and capital expenditures 0.00, giving a free cash flow of -5.29M billion.
Operating Cash Flow-5.29M
Free Cash Flow-5.29M
Free Cash Flow per Share-0.44
Dividends & Yields
Zelira Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.48
52-Week Price Change-3.45%
50-Day Moving Average0.27
200-Day Moving Average0.37
Relative Strength Index (RSI)73.65
Average Volume (3m)36.00
Important Dates
Zelira Therapeutics upcoming earnings date is Aug 27, 2025, TBA Not Confirmed.
Last Earnings DateFeb 26, 2025
Next Earnings DateAug 27, 2025
Ex-Dividend Date―
Financial Position
Zelira Therapeutics as a current ratio of 0.60, with Debt / Equity ratio of 1.46%
Current Ratio0.60
Quick Ratio0.42
Debt to Market Cap1.55
Net Debt to EBITDA-0.15
Interest Coverage Ratio-8.03
Taxes
In the past 12 months, Zelira Therapeutics has paid -919.74K in taxes.
Income Tax-919.74K
Effective Tax Rate0.02
Enterprise Valuation
Zelira Therapeutics EV to EBITDA ratio is -0.25, with an EV/FCF ratio of -2.05.
EV to Sales94.93
EV to EBITDA-0.25
EV to Free Cash Flow-2.05
EV to Operating Cash Flow-2.05
Balance Sheet
Zelira Therapeutics has $38.19K in cash and marketable securities with AU$6.30M in debt, giving a net cash position of $6.26M billion.
Cash & Marketable Securities$38.19K
Total DebtAU$6.30M
Net Cash$6.26M
Net Cash Per Share$0.53
Tangible Book Value Per Share-$0.43
Margins
Gross margin is -5.90%, with operating margin of -6253.93%, and net profit margin of -38513.04%.
Gross Margin-5.90%
Operating Margin-6253.93%
Pretax Margin-39661.61%
Net Profit Margin-38513.04%
EBITDA Margin-38378.53%
EBIT Margin-37914.41%
Analyst Forecast
The average price target for Zelira Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―